Cardinal Health, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Cardinal Health, Inc. stock analysis CAH overview
Somewhat Bullish +50

Cardinal Health reports Q3 results, raises outlook

💰 Cardinal Health reported Q3 fiscal year 2026 revenues of $6.09 billion (11% increase YoY).

⚠️ GAAP operating earnings fell 30% to $509 million due to a $184 million goodwill impairment in Navista & ION units.

📊 Non-GAAP operating earnings rose 18% to $956 million as lower tax rates and share counts offset higher interest expenses.

🗣️ CEO Jason Hollar praised the quarter's resilience, stating strong performance in pharma and specialty solutions positions them for long-term value.

💊 Pharmaceutical and specialty solutions revenue grew 11% to $5.61 billion driven by brand and specialty sales from existing customers.

📈 Profits in the pharmaceutical and specialty segment increased 18% to $784 million thanks to positive generics program performance.

🏥 Global medical products and distribution revenue remained flat YoY as lower volumes were offset by Cardinal Health's own brand growth.

📉 Medical products segment profit dropped 36% to $25 million, primarily due to the adverse net impact of tariffs.

🛠️ Other segment revenue jumped 31% to $1.7 billion, fueled by growth in at-home solutions, nuclear/precision health, and logistics.

💹 The "Other" segment profit climbed 34% to $179 million driven by acquisitions like Advanced Diabetes Supply and OptiFreight Logistics.

🏆 AmerisourceBergen, AbbVie, and Cardinal Health earned perfect scores in the Barron's 500 list of largest US/Canadian publicly traded companies.

📐 The top three companies received perfect 4.0 grade point averages based on return on investment and sales growth metrics.

Bullish Signals
  • Cardinal Health reported third quarter fiscal year 2026 revenues of $60.9 billion, representing an increase of 11% from the prior year.
  • Non-GAAP operating earnings increased 18% to $956 million, with diluted EPS rising 35% to $3.17.
  • The pharmaceutical and specialty solutions segment showed strong growth, with revenue increasing 11% to $56.1 billion.
  • Profit within the pharmaceutical and specialty solutions segment increased 18% to $784 million, driven by positive generics program performance.
  • Revenue in the 'other' segment surged 31% to $1.7 billion, driven by growth in at-Home solutions, nuclear and precision health, and OptiFreight Logistics.
  • Profit for the 'other' segment increased 34% to $179 million, further validating strong performance across its diverse portfolio.
  • CEO Jason Hollar stated that an excellent third quarter extends fiscal 2026 momentum due to the durability and resilience of the business.
  • Management raised their fiscal 2026 outlook based on strong operating performance and confidence in long-term value creation.
  • The company received perfect scores in Barron's 500 list, earning a 4.0 grade point average alongside major peers like AmerisourceBergen and AbbVie.
Risk Factors
  • Third quarter GAAP operating earnings decreased 30% to $509 million, with GAAP diluted EPS dropping 20% to $1.69.
  • The company recorded a significant $184 million pre-tax goodwill impairment in its Navista & ION reporting unit due to changes in the risk profile of business plans and an increased discount rate.
  • Third quarter revenue for the global medical products and distribution segment remained flat, reflecting lower distribution volumes.
  • Global medical products and distribution segment profit decreased 36% to $25 million, primarily driven by the adverse net impact of tariffs.
  • The overall earnings guidance raise relies on momentum that could be offset by high interest and other expenses noted in the non-GAAP calculations.
Full Analysis
Cardinal Health reported its third quarter fiscal year 2026 results with total revenues reaching $60.9 billion, representing an 11% increase compared to the same period in fiscal year 2025. While GAAP diluted earnings per share dropped 20% to $1.69 and operating earnings fell 30% to $509 million, these declines were largely attributed to a significant $184 million pre-tax goodwill impairment charge within its Navista & ION reporting unit, which resulted from changes in risk profiles leading to higher discount rates. Conversely, non-GAAP diluted EPS rose 35% to $3.17, supported by an 18% increase in operating earnings to $956 million, lower effective tax rates, and a reduced share count, though this growth was partially offset by higher interest and other expenses. Segment performance showed mixed but generally positive trends across the company's operations, with the pharmaceutical and specialty solutions segment leading the way. This core division recorded revenue of $56.1 billion, up 11% year-over-year, driven by growth in brand and specialty pharmaceutical sales from existing customers, alongside an 18% profit increase to $784 million due to strong performance in both brand products and the generics program. The global medical products and distribution segment saw revenue remain flat compared to the prior year, as lower distribution volumes were counterbalanced by Cardinal Health's own brand growth, though profits fell 36% to $25 million primarily due to the adverse financial impact of tariffs. The "other" segment experienced notable expansion with revenue jumping 31% to $1.7 billion and profit rising 34% to $179 million, fueled by growth in at-Home solutions—aided by the recent acquisition of Advanced Diabetes Supply—as well as nuclear and precision health solutions and OptiFreight Logistics. CEO Jason Hollar characterized the quarter as excellent and an extension of momentum for fiscal year 2026, citing durability and resilience in the business which positions Cardinal Health for long-term value creation. Consequently, following the strong operating performance led by pharmaceuticals and specialty solutions, the company decided to raise its fiscal 2026 outlook once again. Additionally, Cardinal Health was recognized alongside AmerisourceBergen and AbbVie with perfect scores on the Barron’s 500 list for its sales volume and return on investment metrics.